Pannaree PiromkraipakKant SangpairojWuttipong TirakotaiKulathida ChaithirayanonSupeenun UnchernPorntip SupavilaiChristopher PowerPornpun VivithanapornUniversity of AlbertaFaculty of Medicine, Thammasat UniversityMahidol UniversityPrasat Neurological Institute2019-08-232019-08-232018-03-01Cellular and Molecular Neurobiology. Vol.38, No.2 (2018), 559-57315736830027243402-s2.0-85020688409https://repository.li.mahidol.ac.th/handle/20.500.14594/45232© 2017, Springer Science+Business Media, LLC. Glioblastoma is one of the most malignant and aggressive types of brain tumors. 5-lipoxygenase and cysteinyl leukotriene receptor 1 (CysLT1) play a role in human carcinogenesis. Leukotriene receptor antagonists (LTRAs), anti-asthmatic drugs with mild side effects, have anti-metastatic activity in epidermoid carcinoma, lung carcinoma, and colon cancers as well as neuroprotective effects. Herein, anti-migratory effects of two LTRAs, montelukast and zafirlukast, were investigated in glioblastoma cells. The level of CysLT1 in A172 cells was increased by 3.13 folds after IL-1β treatment. The median toxic concentration of LTRAs in A172, U373, and primary astrocytes ranged from 7.17 to 26.28 μM at 24-h post-exposure. Both LTRAs inhibited migration and invasion of glioma. Additionally, both drugs significantly inhibited the expression and activities of MMP-2 and MMP-9 in A172 and U373 glioblastoma cells and primary human astrocytes, suggesting that CysLT1 plays a role in migration and invasion of glioma, and LTRAs are potential drugs to reduce migration and invasion.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyNeuroscienceArticleSCOPUS10.1007/s10571-017-0507-z